Skip to content
lifestyle.rogueimc.org
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Kelun-Biotech
Final OS Analysis Results from Phase III OptiTROP-Lung04 Study of Sacituzumab Tirumotecan (sac-TMT) Presented at 2026 ESMO
October 25, 2026
The Results of Phase III OptiTROP-Lung06 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ESMO Oral Presentation and Simultaneously Published in The New England Journal of Medicine
October 25, 2026
Kelun-Biotech to Present Multiple Study Results at ESMO 2026
October 15, 2026
Multiple Sacituzumab Tirumotecan (sac-TMT) Studies Selected as LBAs at ESMO 2026, OptiTROP-Lung04 and OptiTROP-Lung06 to be Presented in the Lung Cancer Session
September 22, 2026
Results from Phase III Study of Trastuzumab Botidotin versus T-DM1 in HER2-Positive Breast Cancer Published in JCO
September 14, 2026
SKB378/WIN378 Asthma Drug Shows Positive Phase 2 Results, Moves to Phase 3
September 8, 2026
Kelun-Biotech Announces 2026 Interim Results
August 18, 2026
NMPA Accepts New Indication Application for Sacituzumab Tirumotecan (sac-TMT) as First-Line Treatment for Advanced TNBC
July 30, 2026
Kelun-Biotech Receives a Clinical Trial Notice for Its First Dual-payload ADC SKB565
July 27, 2026
Translational Research Results of Sacituzumab Tirumotecan (sac-TMT) in Combination with Osimertinib as First-Line Treatment for EGFR-Mutant NSCLC Published in Cancer Cell
June 22, 2026
1
2
Next Page
→